Aspirin for primary prevention of cardiovascular disease?

Drug and Therapeutics Bulletin

Volumn 47, Issue 11, 2009, Pages 122-125

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; EUROPEAN UNION; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; LONG TERM CARE; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEX DIFFERENCE; ARTICLE; DIABETIC ANGIOPATHY; META ANALYSIS; OFF LABEL DRUG USE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; HUMANS; META-ANALYSIS AS TOPIC; OFF-LABEL USE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS;

EID: 77649216020     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2009.10.0045     Document Type: Review

References (26)

1. Office for National Statistics, 2009. Health Statistics Quarterly; No. 43, Autumn 2009 [online]. Available: http://www.statistics.gov.uk/ downloads/theme-health/HSQ43.pdf [Accessed 21 October 2009].
2. Fourth Joint Taskforce of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: an executive summary. Eur J Cardio Prev Rehab 2007; 14: E1-40.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
4. Scottish Intercollegiate Guidelines Network, 2007. Risk estmation and the prevention of cardiovasular disease. A national clinical guideline. 97 [online]. Available: http://www.sign.ac.uk/pdf/sign97.pdf [Accessed 21 October 2009].
5. British Cardiac Society et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: v1-52.
6. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
7. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-7.
8. de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001; 1: 1.
9. The National Collaborating Centre for Chronic Conditions, 2008. Type 2 diabetes. National clinical guideline for management in primary and secondary care (update) [online]. Available: http://www.nice.org.uk/nicemedia/pdf/ CG66FullGuideline0509.pdf [Accessed 21 October 2009].
10. Medicines and Healthcare products Regulatory Agency, 2009. Aspirin: not licensed for primary prevention of thrombotic vascular disease. Drug Safety Update 2009; 3: 10-1
11. Fourth Joint Taskforce of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardio Prev Rehab 2007; 14: S1-113.
12. Hart RG et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypothesis. Arch Neurol 2000; 57: 326-32.
13. Sanmuganathan PS et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265-71.
14. Hayden M et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-72.
15. Eidelman RS et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10.
16. ETDRS Investigators. Aspirin effects on mortality and morbidity on patients with diabetes mellitus. Early Treatment Diabetes Retinopathy Study Report14. JAMA 1992; 268: 1292-300.
17. Peto R et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-6.
18. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
19. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
20. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-2.
21. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
22. Lip GYH, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD003186. DOI: 10.1002/14651858.CD003186.pub2. [Last assessed as up-to-date 24 May 2004].
23. Ridker PM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
24. Berger JS et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-13.
25. Belch J et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
26. Ogawa H et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. JAMA 2008; 300: 2134-41